VTE (N=365) | AF (N=883) | VTE and AF (N=56) | Total (N=1304) | |
Mean age in years (SD) | 66.8 (12.6) | 76.8 (8.6) | 77.4 (9.3) | 74.0 (10.9) |
Male sex (n, %) | 171 (46.8) | 484 (54.8) | 26 (46.4) | 681 (52.2) |
Type of cancer (n, %) | ||||
Gastrointestinal | 63 (17.3) | 158 (17.9) | 7 (12.5) | 228 (17.5) |
Lung | 64 (17.5) | 122 (13.8) | 8 (14.3) | 194 (14.9%) |
Breast | 44 (12.1) | 93 (10.5) | 8 (14.3) | 145 (11.1%) |
Prostate | 25 (6.8) | 65 (7.4) | 2 (3.6) | 92 (7.1%) |
Urogenital | 41 (11.2) | 114 (12.9) | 9 (16.1) | 164 (12.6) |
Haematologic | 31 (8.5) | 61 (6.9) | 4 (7.1) | 96 (7.4) |
Skin | 25 (6.8) | 171 (19.4) | 11 (19.6) | 207 (15.9) |
Other | 72 (19.7) | 99 (11.2) | 7 (12.5) | 178 (13.7) |
Type of anticoagulant (n, %) | ||||
VKA | 100 (27.4) | 528 (59.8) | 27 (48.2) | 655 (50.2) |
Heparin | 1 (0.3) | 2 (0.2) | 0 | 3 (0.2) |
LMWH | 182 (49.9) | 92 (10.4) | 11 (19.6) | 285 (21.9) |
DOAC | 82 (22.5) | 261 (29.6) | 18 (32.1) | 361 (27.7) |
AF, atrial fibrillation; DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; VKA, Vitamin K antagonist; VTE, venous thromboembolism.